Sherlock Daniel, Ahdi Hardeep S, Mehta Raju
Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, USA.
Critical Care Medicine, Advocate Lutheran General Hospital, Park Ridge, USA.
Cureus. 2023 Apr 22;15(4):e37990. doi: 10.7759/cureus.37990. eCollection 2023 Apr.
Patients with rheumatoid arthritis (RA) may experience complications directly from the disease process or from immune-modulating agents used to treat RA. Adalimumab is a recombinant human monoclonal antibody directed against tumor necrosis factor alpha (TNFα) which has been increasingly used in the management of inflammatory and autoimmune diseases. Acute lung injury has been associated with the use of anti-TNFα agents, but the association with adalimumab is rare. Here we present a case of a patient with RA-associated lung disease who developed acute respiratory distress syndrome while being treated with adalimumab. Adalimumab-related lung injury is less common than lung injury associated with other anti-TNFα drugs, thus clinicians should be aware of this condition, as prompt recognition and supportive management can help prevent worsening outcomes.
类风湿关节炎（RA）患者可能会直接因疾病进程或用于治疗RA的免疫调节药物而出现并发症。阿达木单抗是一种重组人单克隆抗体，靶向肿瘤坏死因子α（TNFα），已越来越多地用于治疗炎症性和自身免疫性疾病。急性肺损伤与抗TNFα药物的使用有关，但与阿达木单抗的关联较为罕见。在此，我们报告一例患有RA相关肺部疾病的患者，在接受阿达木单抗治疗时发生了急性呼吸窘迫综合征。与阿达木单抗相关的肺损伤比与其他抗TNFα药物相关的肺损伤少见，因此临床医生应了解这种情况，因为及时识别和支持性治疗有助于防止病情恶化。
